Sept 24 (Reuters) - Merck (MRK.N), opens new tab said on Thursday its injectable drug for a serious eye disease affecting people with diabetes was as effective as the current standard treatment in ...

Merck will present data at the American Academy of Ophthalmology Annual Meeting next month. (Angus Liu/Fierce Pharma) Merck & Co.’s Brunello trial has hit its primary endpoint, shedding light on the ...

In the case of Merck and Moderna’s intismeran, the vaccine mechanism is therapeutic—it instructs the immune system to destroy an existing tumor, resulting in the partners’ reported survival benefits.

Merck stock sits near analyst targets that fall short of $200, yet a compressed fall calendar of FDA decisions and a pivotal cancer vaccine readout could force Wall Street to rethink the entire ...

This voice experience is generated by AI. Learn more. This voice experience is generated by AI. Learn more. Merck's stock has surged an impressive 73% over the past year, fueled by a successful mRNA ...

Patients who received the personalized vaccine alongside Keytruda went longer before their cancer returned, and longer before it spread to distant parts of the body, than patients who received ...

An experimental personalized mRNA-based cancer vaccine from Merck and Moderna was successful at preventing melanoma from returning or spreading in a late-stage trial of high risk patients, the ...

Merck MRK.N and Moderna MRNA.O said on Wednesday a study of a personalized mRNA vaccine combined with the immunotherapy drug Keytruda reduced melanoma skin cancer recurrence and spread compared with ...

A personalized messenger RNA cancer treatment developed by Moderna and Merck enabled melanoma patients to live longer without signs of their disease coming back, results the companies say mark the ...

Merck & Co. boosted its 2026 sales outlook after strong demand for newer drugs like Winrevair helped to drive revenues higher in the second quarter. Sales will be between $66.3 billion and $67.3 ...

Merck beat second-quarter estimates and hiked its revenue outlook, as a slate of new products showed strong growth. But the pharmaceutical giant cut its profit guidance due to a charge tied to its ...

Quarterly loss of 13 cents per share includes Terns deal charge Company sees strong uptake of Keytruda QLEX version Keytruda keeps growing, up 5% to $8.37 billion in Q2 Animal health and Gardasil ...